Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Celcuity in a research report issued on Monday, April 28th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.94) per share for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. Leerink Partnrs also issued estimates for Celcuity’s Q2 2025 earnings at ($1.06) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($4.25) EPS, FY2026 earnings at ($3.58) EPS and FY2027 earnings at $0.28 EPS.

Celcuity (NASDAQ:CELC) last posted its earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13).

Other equities analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a report on Tuesday, April 1st. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Celcuity in a report on Friday, April 11th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $30.17.

Celcuity Price Performance

Celcuity stock opened at $10.80 on Thursday. Celcuity has a 52 week low of $7.58 and a 52 week high of $19.77. The business has a 50-day simple moving average of $10.01 and a 200 day simple moving average of $12.10. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $408.66 million, a price-to-earnings ratio of -4.14 and a beta of 0.44.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Summit Investment Advisors Inc. grew its holdings in shares of Celcuity by 49.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after purchasing an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Celcuity in the fourth quarter worth approximately $50,000. Focus Financial Network Inc. bought a new position in shares of Celcuity in the first quarter worth approximately $108,000. GAMMA Investing LLC grew its holdings in shares of Celcuity by 1,237.4% in the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company’s stock worth $131,000 after purchasing an additional 1,225 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Celcuity in the fourth quarter worth $142,000. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.